melanocortin 4 receptor


Also found in: Acronyms.

MC4R

A gene on chromosome 18q22 that encodes a receptor for alpha, beta and gamma melanocyte stimulating hormone (MSH), the activity of which is mediated by G protein-activated adenylate cyclase and expressed in the brain, placenta and gut.

Molecular pathology
Defects in MC4R are linked to obesity.

melanocortin 4 receptor (MC4R)

A cell receptor that is strongly stimulated by the alpha melanocyte-stimulating hormone-a peptide that produces a sense of fullness after eating. Mutations of the gene that codes for MC4R are commonly associated with severe uncontrollable overeating and pathological obesity. Such mutations can be found in nearly 6 per cent of people with a life-long history of obesity.
References in periodicals archive ?
Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene.
[3] Genes: POMC, proopiomelanocortin; PC1, prohormone convertase 1; MC4R, melanocortin 4 receptor; Pcskl, proprotein convertase subtilisin/kexintype 1; SIM1, single-minded family bHLH transcription factor 1; BDNF, brain-derived neurotrophic factor; Pmch, promelanin concentrating hormone; NTRK2, neurotrophic receptor tyrosine kinase 2; SNRPN, small nuclear ribonucleoprotein polypeptide N; SNURF, SNRPN upstream reading frame.
Subhedar, "Central administration of selective melanocortin 4 receptor antagonist HS014 prevents morphine tolerance and withdrawal hyperalgesia," Brain Research, vol.
Association of a melanocortin 4 receptor (MC4R) polymorphism with performance traits in Lithuanian White pigs.
Association of melanocortin 4 receptor (MC4R) and high mobility group AT-hook 1 (HMGA1) polymorphisms with pig growth and fat deposition traits.
A novel melanocortin 4 receptor (MC4R) gene mutation associated with morbid obesity.
Binge eating as a major phenotype of melanocortin 4 receptor gene mutations.
In the future, drugs that mimic the melanocortin 4 receptor protein may compensate for the defective gene.
Several mutations in the melanocortin 4 receptor gene are associated with obesity in Chinese children and adolescents.
Rhythm, a biopharmaceutical company, has started two Phase 2 clinical trials focused on assessing the safety and effectiveness of setmelanotide, the company's novel melanocortin 4 receptor (MC4R) agonist for the treatment of Prader-Willi Syndrome and POMC-null obesity, it was reported on Friday.
O'Rahilly, "Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene," New England Journal of Medicine, vol.